Xencor, Inc Loss Contingency Accrual
Xencor, Inc (XNCR) had Loss Contingency Accrual of $0 as of 2017-12-31, per its 10-K filed 2019-02-26.
Discontinued › Notes › Commitment and Contingencies › Loss Contingency
us-gaap:LossContingencyAccrualAtCarryingValue · last filed 2019-02-26
- 2017-12-31: Loss Contingency Accrual $0.00.
- 2016-12-31: Loss Contingency Accrual $2.35M; Loss Contingency Accrual as first filed $0.00.
- 2016-09-30: Loss Contingency Accrual $0.00.
- 2016-06-30: Loss Contingency Accrual $0.00.
| Period end | Loss Contingency Accrual | Loss Contingency Accrual as first filed |
|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2019-02-26 | |
| 2016-12-31 | $2.35M 10-K · filed 2019-02-26 | $0.00 10-K · filed 2017-03-01 |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-02 | |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |